{rfName}

Indexed in

License and use

Icono OpenAccess

Citations

9

Altmetrics

Analysis of institutional authors

Marti Domenech, M JosepAuthorBotí González, María De Los ángelesAuthor

Share

Publications
>
Article

Predictors of clinically significant quality of life impairment in Parkinson's disease

Publicated to:Npj Parkinsons Dis. 7 (1): 118-118 - 2021-01-01 7(1), DOI: 10.1038/s41531-021-00256-w

Authors: Santos García D; de Deus Fonticoba T; Cores C; Muñoz G; Paz González JM; Martínez Miró C; Suárez E; Jesús S; Aguilar M; Pastor P; Planellas L; Cosgaya M; García Caldentey J; Caballol N; Legarda I; Hernández Vara J; Cabo I; López Manzanares L; González Aramburu I; Ávila Rivera MA; Catalán MJ; Nogueira V; Puente V; Ruíz de Arcos M; Borrué C; Solano Vila B; Álvarez Sauco M; Vela L; Escalante S; Cubo E; Carrillo Padilla F; Martínez Castrillo JC; Sánchez Alonso P; Alonso Losada MG; López Ariztegui N; Gastón I; Clavero P; Kulisevsky J; Blázquez Estrada M; Seijo M; Rúiz Martínez J; Valero C; Kurtis M; de Fábregues O; González Ardura J; Ordás C; López Díaz LM; McAfee D; Martinez-Martin P; Mir P; COPPADIS Study Group COPPADIS Study Group

Affiliations

Abstract

Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R2 = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.© 2021. The Author(s).

Keywords

Cellular and molecular neuroscienceNeurologyNeurology (clinical)Neurosciences

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Npj Parkinsons Dis due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 25/275, thus managing to position itself as a Q1 (Primer Cuartil), in the category Neurosciences. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 10.57, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-07, the following number of citations:

  • Europe PMC: 9
  • Open Alex: 26
  • OpenCitations: 20

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-07:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 56.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 55 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 6.25.
  • The number of mentions on the social network X (formerly Twitter): 14 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.